Study Summary
This trial will test how well a new drug works in people with cancer that has returned or does not respond to treatment.
- Dose Escalation for Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
- Immune Checkpoint Refractory Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 4 Secondary · Reporting Duration: Up to 2 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
3 Treatment Groups
Arm A: mRNA-2752
1 of 3
Arm C: mRNA-2752 Alone or mRNA-2752 + Durvalumab
1 of 3
Arm B: mRNA-2752 + Durvalumab
1 of 3
Experimental Treatment
264 Total Participants · 3 Treatment Groups
Primary Treatment: mRNA-2752 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 17 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Srikrishna, Devabhaktuni, and Kris Sachsenmeier. 2021. “We Need to Bring R0 Genome Medicine. Springer Science and Business Media LLC. doi:10.1186/s13073-021-00940-9.
- Srikrishna, Devabhaktuni, and Kris Sachsenmeier. 2021. “We Need to Bring R0 Genome Medicine. Springer Science and Business Media LLC. doi:10.1186/s13073-021-00940-9.
- 2018. "Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03739931.
Frequently Asked Questions
Has the FDA given their blessing to mRNA-2752?
"So far, mRNA-2752 has only been minimally tested for safety and efficacy, thus earning a score of 1." - Anonymous Online Contributor
What illnesses does mRNA-2752 typically target?
"mRNA-2752 is widely employed to treat unresectable stage III non-small cell lung cancer, as well as previously untreated metastatic urothelial carcinoma and advanced directives." - Anonymous Online Contributor
Are there any locales currently administering this research project within city boundaries?
"The Sarah Cannon Research Institute in Nashville, the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, and Yale Cancer Center in New Haven are some of the 15 active sites for this study. Other locations also exist which qualify for enrolment." - Anonymous Online Contributor
What is the scope of participants in this clinical exploration?
"AstraZeneca, the sponsor of this trial, needs to recruit 264 candidates that meet their set inclusion criteria. These patients will be sourced from multiple medical centres including Sarah Cannon Research Institute in Nashville and UCSF Helen Diller Family Comprehensive Cancer Center located in San Francisco." - Anonymous Online Contributor
Are there any vacancies available for individuals to partake in this research?
"Affirmative. Clinicaltrials.gov states that, as of July 14th 2022, this research is actively enrolling 264 patients across 15 medical facilities. The trial was initially posted on November 27th 2018 and has been modified since then." - Anonymous Online Contributor
Are there any prior investigations involving mRNA-2752 that have been documented?
"Currently, 333 clinical trials are underway studying the effects of mRNA-2752 with 52 studies at Phase 3. Most locations for these trials are located in Cordoba, Texas; however, this medication is being trialed across 12961 centers globally." - Anonymous Online Contributor